Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Iodine Refractory Thyroid Cancer
NCT00519896Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jul 2007
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Differentiated Thyroid Carcinoma (DTC) and Medullary Thyroid Carcinoma (MTC), sponsored by University of Washington. Primary endpoint: Overall Response Rate up to 100 months. Started Jul 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
Differentiated Thyroid Carcinoma (DTC)Medullary Thyroid Carcinoma (MTC)
Beyond the preview
Go deeper on NCT00519896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00519896.